Argenx : Résultats de phase 2 positifs dans le syndrome de Sjögren
>Phase 2 soutenant un passage en phase 3 - Argenx annonce des résultats positifs de la phase 2 RHO évaluant efgartigimod chez des patients atteints du syndrome de Sjögren (SjD). La société ne communique aucun résultat chiffré à ce stade puisqu’ils seront présentés lors d’un prochain congrès médical. Sur la base de ces résultats, la société envisage de poursuivre le développement d’efgartigimod en phase 3, ce qui pourrait conduire à un lancement commercial dans cette i...Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.